ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the lead plaintiff deadline of October 6, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Altimmune securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 6, 2025 [2]. - The lawsuit alleges that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker for fibrosis reduction [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in securities class action settlements [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3].